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public health importance. While smokers
may have the right to smoke, nonsmok-
ers should have the right to be protected
from harm resulting from the action of
smokers. Reduction of exposure to ETS
should be the goal of all nations.
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P R E V I E W S
The E type cyclins and their catalytic
partner, CDK2, participate in the regula-
tion of retinoblastoma protein inactiva-
tion, establishment of the prereplication
complex (pre-RC), and initiation of S
phase (Figure 1); their participation in
these critical regulatory steps has result-
ed in the assumption that both cyclin E
and CDK2 are indispensable for cell
cycle progression. Support for this notion
was initially provided by experiments uti-
lizing a dominant negative CDK2 mole-
cule to demonstrate that CDK2 activity is
required for cell cycle progression of cer-
tain tumor-derived cell lines (van den
Heuvel and Harlow, 1993). An essential
role for E/CDK2 has two critical implica-
tions. First, as an essential enzyme, loss
of either component should impede
cell cycle progression. Second, as
unchecked cell proliferation is a hallmark
of human cancer, the cyclin E/CDK2
kinase should be a logical target for the
development of anticancer therapeutics.
In point of fact, cyclin E is overexpressed
in human breast cancer, and its overex-
pression correlates with poor prognosis
(Keyomarsi et al., 2002). However, two
papers now challenge the notion that the
cyclin E/CDK2 kinase is an essential
component of the cell cycle machine.
In one approach, cyclin E was elimi-
nated from the mouse via targeting of
both genes encoding E type cyclins,
cyclins E1 and E2 (Geng et al., 2003),
and in the second, CDK2 itself was dis-
rupted (Ortega et al., 2003). While the
phenotypes are not entirely overlapping
as one might expect, they do culminate
with the startling revelation that neither E
type cyclins nor CDK2 are strictly
required for either embryonic develop-
ment or for continuous cell cycle pro-
gression.
As with elimination of another G1
cyclin, cyclin D1 (Sicinski et al., 1995),
the elimination of E type cyclins resulted
in focal abnormalities. Defects were
observed in the development of cell
types that required repeated rounds of
endoreplication (repeated rounds of S
phase without intervening cell division)
such as trophoblast giant cells. Such a
phenotype might have been anticipated
from earlier examination of cyclin E func-
tion in Drosophila development (Sauer
and Lehner, 1995). Surprisingly, CDK2
ablation did not result in apparent
defects in endoreplication cycles.
Defects were also observed in spermato-
genesis in E2−/− and E1/E2−/− mice that
resulted in eventual male sterility.
CDK2−/− mice, like cyclin E deficient
mice, also exhibited defects in male
spermatogenesis. Additionally, CDK2−/−
mice also exhibited defective female
gametogenesis, implicating the cyclin
E/CDK2 kinase in the regulation of mei-
otic cell cycles.While it is far from settled,
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G1 is the phase of the cell cycle wherein the cell is responsive to growth factor-dependent signals. As such, G1 regulation
is frequently disrupted in cancer through deregulation of cyclin/CDK activity; deregulation of G1 phase provides tumori-
genic cells with a growth advantage. Cyclin E, the regulatory cyclin for CDK2, is considered a requisite regulator of G1 pro-
gression. Cyclin E is overexpressed in cancer, suggesting that cyclin E/CDK2 deregulation contributes to tumorigenesis.
Two papers now challenge both the concept that cyclin E/CDK2 is a requisite component of the cell cycle machine and
efforts to develop cyclin E/CDK2 inhibitors as antiproliferative therapeutics.
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the fact that CDK2 ablation fails to result
in the defective endoreplication cycles
observed in the E knockout suggests
that E type cyclins have CDK2-indepen-
dent functions (see below).
Is removal of the cyclin E/CDK2
kinase really of no consequence to cell
cycle progression? To address this issue,
both groups established primary cultures
of embryonic fibroblasts (MEFs). Both
cyclin E- and CDK2-deficient MEFs
exhibited normal cell cycle distributions
under conditions of continuous prolifera-
tion. The lack of any detectable pheno-
type under these conditions potentially
results from functional redundancy
among the various CDK complexes.
While arguments could be made regard-
ing whether a cyclin D/CDK4 or a cyclin
A/CDC2 complex is the preeminent
redundant kinase, it is likely that both
contribute in the absence of a functional
cyclin E/CDK2 kinase.
While no defect was noted in contin-
uously proliferating cells, when cell cycle
reentry was examined, defects were
observed, and the cohesion between the
E1/E2−/− and CDK2−/− phenotypes once
again blurs. While G0 to S phase pro-
gression appears essentially unper-
turbed in CDK2−/− fibroblasts, E1/E2−/−
MEFs fail to reenter the cell cycle.
Mechanistically, the defect in the cyclin
E-deficient cells results from the inability
of these cells to fully establish a pre-RC
at origins of replication. Formation of the
pre-RC requires the ordered assembly of
multiple proteins at sites of DNA replica-
tion initiation (Bell, 2002). The origin
recognition complex binds first, followed
by CDC6 and cdt1, which together
recruit the hexameric minichromosome
maintenance complex (MCM2-7), the
putative replicative helicase. The devel-
opment of cell-free replication assays
has revealed that the cyclin E/CDK2
kinase functions synergistically with
CDC6 to facilitate MCM loading
(Coverley et al., 2002). The inability of
the MCM hexamer to associate with
chromatin during cell cycle reentry sup-
ports the notion that cyclin E performs an
essential, nonredundant role in pre-RC
establishment.
While the defect in MCM loading in
the E1/E2−/− MEFs confirms previous
work, the fact that no such defect is
observed in CDK2−/− cells is paradoxical.
Several potential mechanisms can be
envisioned that could resolve this issue.
The first is that another G1 CDK func-
tions in its absence. Consistent with this
idea, the cyclin D1/CDK4 kinase does
associate with the pre-RC (Gladden and
Diehl, 2003). However, it remains to be
demonstrated that a cyclin D1/CDK4
complex can actually drive mature pre-
RC formation. A second possibility is that
cyclin E binds to another CDK, such as
CDK3, to perform its critical function.
However, the CDK3 gene is disrupted by
a premature termination codon in most
strains of laboratory mice, eliminating it
as a potential partner (Ye et al., 2001). A
third possibility is that cyclin E can asso-
ciate with an as yet unidentified kinase
and thereby promote S phase. However,
lack of detectable catalytic activity asso-
ciated with cyclin E in the CDK2−/− cells
argues against this possibility. Finally, it
is possible that E type cyclins have an
intrinsic CDK-independent function that
is wholly unrelated to their capacity to
promote activation of an established pro-
tein kinase.
There are currently a number of
small molecular weight compounds that
target CDK2. If proliferating cells can cir-
cumvent CDK2 loss or inhibition, will
therapeutics that target the CDK2 kinase
be efficacious? The capacity of cells
lacking either cyclin E or CDK2 to contin-
uously proliferate suggests that normal
somatic cells should withstand therapeu-
tics that specifically target CDK2 with lit-
tle adverse effect. The question is, will
tumor cells display increased sensitivity
to CDK2 inhibition, perhaps due to their
inherently increased proliferative capaci-
ty? The continued proliferation of colon
cancer derived cell lines following inhibi-
tion of CDK2 (Tetsu and McCormick,
2003) argues that, at the very least, cer-
tain cancer types could be quite refracto-
ry to CDK2-based therapies. The
resistance of the colon cancer cells to
CDK2 inhibition likely reflects redundan-
cy between G1 cyclin-dependent kinas-
es; given that cyclin D1 is frequently
overexpressed in colon cancer, its
deregulation could drive cell cycle pro-
gression in the absence of the cyclin
E/CDK2 kinase. Still, if CDK2 inhibitors
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Figure 1. Regulatory activities of the cyclin
E/CDK2 kinase
G1 to S phase progression is coordinated by
the sequential activities of the cyclin D-
dependent kinase and the cyclin E/CDK2
kinase. The D type and E type kinases func-
tion to sequentially inactivate the transcrip-
tional repression activity of Rb family proteins
prior to restriction point (R point) passage.
The cyclin E/CDK2 kinase is then thought to
perform a number of additional functions
necessary for S phase entry. These include
phosphorylation of nucleophosmin, which is
necessary for centrosome duplication, phos-
phorylation of NPAT, which facilitates histone
synthesis, and establishment of prereplica-
tion complexes (pre-RC) at origins of DNA
replication. While cyclin E/CDK2 complexes
have been demonstrated to phosphorylate
a number of the proteins in the pre-RC, the
functional importance of these phosphoryla-
tion events remains to be established.
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are not effective single agent therapeu-
tics, perhaps they will function in combi-
nation with standard chemotherapeutic
approaches. Inhibition of the cyclin
E/CDK2 kinase could potentially sensi-
tize tumor cells and increase the tumor-
specific killing potential of more
traditional treatment regimes.
A final intriguing phenotype
observed in both the E and CDK2 ablat-
ed mice was the resistance of MEFs
derived from these mice to oncogene-
mediated transformation. Their resis-
tance points toward the potential use of
CDK2-based therapies as chemopreven-
tive agents. While this approach might
not be generally applicable to all individ-
uals, it might provide some benefit to
those with a known genetic predisposi-
tion to cancer. Specific inhibition of
CDK2 in these individuals might help
prevent the overt transformation of cells
sustaining a “second hit.”
The work of Geng et al. and Ortega
et al. challenges the current concepts
regarding the molecular basis of cell
cycle progression and suggests a reex-
amination of the utility of targeting a spe-
cific CDK for cancer therapy. Not only
does this new data challenge many
established paradigms, but it also intro-
duces a new challenge. Can one distinct
molecule be targeted to block cell cycle
progression in the tumor cell? So far, the
answer is no, most likely reflecting the
high degree of built-in redundancy.
Efficacious therapies will have to
address these redundancies, possibly
through the targeting of more than a sin-
gle step in a given pathway. As our
knowledge of the molecular processes
that drive cell proliferation evolves, so
should our ability to design antiprolifera-
tive agents.
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